Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 7Breast Neoplasms 6Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Melanoma 2Gastrointestinal Stromal Tumors 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Thyroid Neoplasms 1Recurrence 1Non-squamous Non-small-cell Lung Cancer 1Non Squamous Non Small Cell Lung 1Neoplasms 1Neoplasm Metastasis 1Neoadjuvant Therapy 1NSCLC 1Gastro-enteropancreatic neuroendocrine tumor 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Cervical Cancer Metastatic 1Carcinoma, Transitional Cell 1BRCA-Mutated Breast Carcinoma 1Advanced Solid Tumor 1Advanced NSCLC 1

Interventions

pembrolizumab 92Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 24Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × famitinib × Clear all
NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
265 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡